文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

将真实世界证据纳入临床开发计划

The inclusion of real world evidence in clinical development planning.
PubMed 文献 · Trials · 2018-08-29

文章提出一个在临床开发计划中系统纳入真实世界证据(RWE)的贝叶斯网络荟萃分析框架,并在多发性硬化症的临床试验模拟中演示。结果显示,纳入RWE后,TRANSFORMS研究每组需284例患者,FREEDOMS和FREEDOMS II研究每组需189例患者,三项III期研究总体样本量减少至少40%,节省至少6个月时间。

要点

  • 提出在临床试验设计阶段整合RCT与RWE的贝叶斯网络荟萃分析框架。
  • 模拟显示纳入RWE可使III期研究样本量减少至少40%。
  • 样本量减少带来至少6个月的时间节省。

核心结论

  • 使用RWE可减少关键III期研究的样本量,并相比不纳入RWE的样本量计算方法显著节省时间。

研究设计与样本

  • 提出一个在临床开发计划中纳入RWE的框架,将RCT和RWE证据在贝叶斯网络荟萃分析中合并,并在关键节点(如II期试验结束时和关键III期研究设计前)进行。
  • 通过临床试验模拟,在多发性硬化症中设计了一个使用RWE的替代临床开发计划。

主要发现

  • 在TRANSFORMS研究中,每组需要284例患者以达到90%把握度检测预定大小的效应。
  • 在FREEDOMS和FREEDOMS II临床试验中,每组需要189例患者。
  • 三项III期研究总体样本量减少至少40%,相当于fingolimod III期项目节省至少6个月时间。

临床怎么用

  • 在临床开发计划的关键节点,可考虑将RWE纳入贝叶斯网络荟萃分析以指导后续试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: When designing studies it is common to search the literature to investigate variability estimates to use in sample size calculations. Proprietary data of previously designed trials in a particular indication are also used to obtain estimates of variability. Estimates of treatment effects are typically obtained from randomised controlled clinical trials (RCTs). Based on the observed estimates of treatment effect, variability and the minimum clinical relevant difference to detect, the sample size for a subsequent trial is estimated. However, data from real world evidence (RWE) studies, such as observational studies and other interventional studies in patients in routine clinical practice, are not widely used in a systematic manner when designing studies. In this paper, we propose a framework for inclusion of RWE in planning of a clinical development programme. METHODS: In our proposed approach, all evidence, from both RCTs and RWE (i.e. from studies in routine clinical practice), available at the time of designing of a new clinical trial is combined in a Bayesian network meta-analysis (NMA). The results can be used to inform the design of the next clinical trial in the programme. The NMA was performed at key milestones, such as at the end of the phase II trial and prior to the design of key phase III studies. To illustrate the methods, we designed an alternative clinical development programme in multiple sclerosis using RWE through clinical trial simulations. RESULTS: Inclusion of RWE in the NMA and the resulting trial simulations demonstrated that 284 patients per arm were needed to achieve 90% power to detect effects of predetermined size in the TRANSFORMS study. For the FREEDOMS and FREEDOMS II clinical trials, 189 patients per arm were required. Overall there was a reduction in sample size of at least 40% across the three phase III studies, which translated to a time savings of at least 6 months for the undertaking of the fingolimod phase III programme. CONCLUSION: The use of RWE resulted in a reduced sample size of the pivotal phase III studies, which led to substantial time savings compared to the approach of sample size calculations without RWE.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Martina R, Jenkins D, Bujkiewicz S, et al. The inclusion of real world evidence in clinical development planning. Trials. 2018. PMID: 30157904. doi:10.1186/s13063-018-2769-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。